Navigation Links
ChemGenex Reports Successful Personalized Dosing of Quinamed at,ASCO

MELBOURNE, Australia & MENLO PARK, Calif.--(BUSINESS WIRE)--Jun 4, 2007 - ChemGenex Pharmaceuticals (ASX: CXS, NASDAQ: CXSP) announced today the presentation of data from its Quinamed(R) (amonafide dihydrochloride) phase 1/2a dose-escalation study, designed to identify a genotypically optimised dose of Quinamed in heavily pre-treated patients with a variety of solid tumors. The key outcomes from this study were (i) demonstration that dose level could be optimised according to patient genotype, (ii) the drug was well tolerated, with predictable and manageable side effects, and (iii) there was evidence of anticancer activity in several solid tumor types.

Dr. John Kuhn of the University of Texas Health Science Center in San Antonio, TX, along with the investigators at Sarah Cannon Cancer Center, TN and University of Louisville, KY discussed the data in an oral presentation at the American Association of Clinical Oncology (ASCO) 43rd Annual Meeting in Chicago, Illinois.

"The clinical activity of amonafide against a variety of cancers has long been recognized, but development has been hampered by the unpredictable side effect profile for patients" said Dr Kuhn. "We are excited by the new opportunities that personalized dosing of Quinamed offers for a range of solid tumor patients who have developed resistance to existing therapies."

Highlights of the presentation included:

-- Confirmation that genotyping of patients prior to treatment allows for optimized personalized dosing and improved drug tolerance.

-- Patients with rapid and intermediate acetylator genotypes (who more rapidly metabolize the drug to the acetylated derivative associated with side effects) achieved a maximum tolerated dose (MTD) of 320 mg/m2 of Quinamed weekly, whilst patients with slow acetylator genotypes achieved an MTD of 400 mg/m2 of Quinamed weekly (three weeks on treatment followed by one week off treatment,
'"/>




Page: 1 2 3 4

Related medicine technology :

1. ChemGenex Reports Successful Personalized Dosing of Quinamed at ASCO
2. Independent Publication Confirms Growing Therapeutic Challenge of T315I Mutation in Patients with CML, Notes ChemGenex
3. Independent Publication Confirms Growing Therapeutic Challenge of T315I Mutation in Patients with CML, Notes ChemGenex
4. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
5. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
6. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
7. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
8. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
9. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
10. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
11. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
Post Your Comments:
(Date:8/28/2014)... Aug. 28, 2014 Pharmatech initiated enrollment ... into this game-changing method for matching cancer patients ... clinical trials target specific cancers, disease staging, and ... for the cancer, in the first place. The ... information may not be well known to the ...
(Date:8/28/2014)... Aug. 28, 2014  In anticipation of the upcoming ... made available for the first time. Industry Overview: Medtech ... offers a snapshot of San Diego,s ... everything from the latest employment statistics to current venture capital ... San Diego such a vital part of the ...
(Date:8/28/2014)... Nonin Medical, Inc., the inventor of finger pulse oximetry ... that the Food and Drug Administration (FDA) has cleared ... use in the United States . ... or kiosk through a USB connector and measures oxygen ... The Model 3231 received EU certification last year. ...
Breaking Medicine Technology:Enrollment in Pharmatech's Revolutionary AccessPPM Program Launches 2New Infographic Published - Overview of Medtech & Life Sciences Industry in San Diego 2Nonin Medical Announces FDA Clearance of Nonin Model 3231 USB Pulse Oximeter 2
... Va., Oct. 6 With October ... Association (NCPA) encourages community pharmacists to demonstrate their ... all aspects of medications, from dispensing to disposal. ... (Logo: http://photos.prnewswire.com/prnh/20100106/DC33253LOGO ) ...
... 6 Baxano, Inc. ( www.baxano.com ) today announced that ... Technology for Spine Care at the 2010 Spine Technology Awards. ... first place in the Best New Technology in Lumbar Care. ... 2010 Spine Technology Awards Gala in Orlando, FL. Baxano, Inc. ...
Cached Medicine Technology:NCPA Encourages Pharmacists to Promote Medication Expertise from Dispensing to Disposal 2NCPA Encourages Pharmacists to Promote Medication Expertise from Dispensing to Disposal 3Baxano, Inc. Awarded Prestigious 2010 Spine Technology Awards 2
(Date:8/29/2014)... PA (PRWEB) August 29, 2014 "After reading ... who don’t stand very often, I decided that there needed ... periods during the day," said a concerned inventor from Sikestons, ... stand for long periods. It builds endurance and keeps the ... better health. Easy to use and producible in design variations, ...
(Date:8/29/2014)... Only a handful of CPR and basic life ... which are consistent with recent health guidelines, according ... Medicine Australasia , the journal for the Australasian ... recognition and treatment of sudden cardiac arrest are ... of Turkish emergency medicine specialists put together the ...
(Date:8/29/2014)... The Fresh Diet, America’s premier gourmet meal ... Vegetarian meal plan. Originating from The Fresh Diet’s commitment ... is designed to satisfy customers seeking a convenient, worry-free ... Responding to the growing demand by customers for non-meat ... (Forbes) with 14% of Americans identifying vegetarian meals as ...
(Date:8/29/2014)... Dennis Thompson HealthDay Reporter , ... during the early days of the Ebola outbreak in West ... mutates and spreads. Researchers report in the Aug. 28 ... determined the following: The Ebola strains responsible for ... to the very first recorded outbreak of Ebola in central ...
(Date:8/29/2014)... N.C (PRWEB) August 29, 2014 VHA ... awards for excellence in clinical care, honoring nine facilities ... the patient experience. , “At Novant Health, providing quality, ... top priority” said Tom Zweng, MD, executive vice president ... commitment to provide a remarkable experience for each and ...
Breaking Medicine News(10 mins):Health News:The Fresh Diet America's #1 At-Home Meal Delivery Company, Debuts Fresh Vegetarian Meal Plan Offering All-Natural Ingredients 2Health News:The Fresh Diet America's #1 At-Home Meal Delivery Company, Debuts Fresh Vegetarian Meal Plan Offering All-Natural Ingredients 3Health News:Gene Research Yields Insights Into Ebola Virus 2Health News:Gene Research Yields Insights Into Ebola Virus 3Health News:Novant Health Recognized for Excellence in Clinical Care 2Health News:Novant Health Recognized for Excellence in Clinical Care 3
... U.S. wildfires are likely to increase in the coming ... the University of Comahue in Argentina and involving the ... outbreaks in the past five centuries with periods of ... ,States like Washington, Oregon, California, Colorado, New Mexico, Arizona ...
... appears that alcohol-induced bone loss resulting from excessive ... or the anti-osteoporosis drug Boniva? (ibandronate), a Loyola ... binge-alcohol drinking reduces bone mass, which is detrimental ... rate of bone loss in osteoporotic post-menopausal women,” ...
... new virus, a modified strain, has led to the death ... Five other pre mature babies are undergoing treatment. ... University Hospital after they were found to be carriers of ... aureus). ,Hospital authorities have confirmed that the baby ...
... Medicine, doctors report on the case of a 35 ... and emergency department //with double vision, slurred speech, drooping ... to be wound botulism. ,Wound botulism is a ... bacterium Clostridium botulinum contaminate a wound, germinate, and produce ...
... promises heavy investment opportunities for Non-Resident Keralites (NRK), making ... long term. ,Kerala Tourism Department has ... 23 – 27 for showcasing the opportunities in the ... a congregation of major hospitals, health insurance companies, policy ...
... approval for consumption of meat and milk from cloned animals ... and John C. Matheson. have declared that it is safe ... offspring. “On no basis can we differentiate the food products ... ,A formal recommendation will be released this week by ...
Cached Medicine News:Health News:New Study Links Western Wildfires to Atlantic Ocean Surface Temperatures 2Health News:New Study Links Western Wildfires to Atlantic Ocean Surface Temperatures 3Health News:Vitamin D or Anti-osteoporosis Drug Reduces Bone Loss from Binge Drinking 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: